{
  "items": [
    {
      "title": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "description": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "published_utc": "2025-05-14T23:38:00",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
      "category": "company",
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134453013,
      "datetime": 1747237080
    },
    {
      "title": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "description": "Dow's 115-point drop led by losses for Amgen, 3M stocks",
      "published_utc": "2025-05-14T19:05:00",
      "source": "MarketWatch",
      "url": "https://finnhub.io/api/news?id=fe994dfedeced3bae800e6590a04318330ed9fec1d3b55e456f1986dc367eb7e",
      "category": "company",
      "image": "",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134437978,
      "datetime": 1747220700
    },
    {
      "title": "A Path To Antibody Protection",
      "description": "In the wake of the 2023 Supreme Court's decision in Amgen, Inc. v Sanofi, the remaining means by which patent practitioners can claim antibodies while satisfying the requirements of 35 U.S.C. ยง 112...",
      "published_utc": "2025-05-14T18:15:16",
      "source": "Finnhub",
      "url": "https://finnhub.io/api/news?id=5029aff2c8e4f1162391f3db0cfa9082bcd8d23b92cdc7f7cac58e229d6d0edb",
      "category": "company",
      "image": "",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134436049,
      "datetime": 1747217716
    },
    {
      "title": "BBH: Fear Of Price Controls Is Not The Problem",
      "description": "The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check out why I rate BBH a sell.",
      "published_utc": "2025-05-14T17:00:00",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=5b9b2ebe607eb4d37afae12d3df292c9ef9d6c96c54e06f280d50c128a84afe4",
      "category": "company",
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200850893/image_2200850893.jpg?io=getty-c-w1536",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134435713,
      "datetime": 1747213200
    }
  ]
}